Rising drug overdose deaths in chronic liver disease in the United States, 2015-2023 [0.03%]
美国2015-2023年慢性肝病患者药物过量死亡率上升
Donghee Kim,Brittany B Dennis,Pojsakorn Danpanichkul et al.
Donghee Kim et al.
Letter to the editor on" Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial. " [0.03%]
关于“HK-660S治疗原发性硬化性胆管炎患者的安全性和有效性：一项随机双盲IIa期临床试验”的来信
Bitao Jiang,Song Zhang,Lingling Bao
Bitao Jiang
So-Young Kim,Eui-Cheol Shin
So-Young Kim
Editorial on "Factors associated with hepatitis B mother-to-child transmission in a national prevention program": Redefining MTCT prevention strategies toward HBV elimination [0.03%]
述评——乙型肝炎母婴阻断失败的相关因素分析：消除乙肝之母传子预防策略的再思考
Eunho Choi,Ji Hoon Kim,Young-Sun Lee
Eunho Choi
Correspondence to "Critical Flaws in the Molecular Classification of HCC Based on Metabolic Zonation" [0.03%]
关于基于代谢分区的肝细胞癌分子分类关键缺陷的通信答复
Tomoko Aoki,Naoshi Nishida,Masatoshi Kudo
Tomoko Aoki
Response to Editorial on Ciociola et al., "Downregulation of the MARC1 p.A165 Risk Allele Reduces Hepatocyte Lipid Content by Increasing Beta-Oxidation" [0.03%]
Ciociola等人的论文“MARC1 p.A165风险等位基因的下调通过增加β氧化来减少肝细胞脂质含量”的社论回应
Ester Ciociola,Tanmoy Dutta,Rosellina M Mancina et al.
Ester Ciociola et al.
Correspondence to editorial on "GLP-1RA may open a new era for MASLD treatment" [0.03%]
关于“GLP-1受体激动剂可能开启慢加素性肝衰治疗新纪元”的来信答复
Xianhua Mao,Mindie H Nguyen
Xianhua Mao
Reply: Early Cancer Risk Reduction After GLP-1RA Use: Signal or Bias? [0.03%]
关于GLP-1受体激动剂使用后早期癌症风险降低的回复：信号还是偏倚？
Xianhua Mao,Mindie H Nguyen
Xianhua Mao